Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | PARP1 | P09874 | 9/20 | 0.50 |
| ▸ | PARP2 | Q9UGN5 | 9/20 | 0.50 |
| ▸ | PARP3 | Q9Y6F1 | 9/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | TNKS | O95271 | 1/20 | 0.49 |
| ▸ | PARP6 | Q2NL67 | 1/20 | 0.49 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.49 |
| ▸ | CFTR | P13569 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4421904 | 0.89 | PARP1 (0.59) | KDM4EALDH1A1TDP1PARP1PARP2 | |
| SCHEMBL4323093 | 0.85 | KDM4E (0.58) | KDM4EALDH1A1TDP1PARP1PARP2 | |
| SCHEMBL4333489 | 0.83 | HSD11B1 (0.69) | ALDH1A1 | |
| SCHEMBL4318289 | 0.83 | KDM4E (0.57) | KDM4EALDH1A1 | |
| SCHEMBL4312385 | 0.81 | MAPK1 (0.62) | KDM4EALDH1A1 | |
| SCHEMBL4422043 | 0.81 | KDM4E (0.52) | KDM4EALDH1A1TDP1PARP1PARP2 | |
| SCHEMBL4319285 | 0.80 | TIPARP (0.48) | PARP1 | |
| SCHEMBL4326371 | 0.79 | SMN1; SMN2 (0.50) | ALDH1A1 | |
| SCHEMBL4415437 | 0.79 | SLC6A7 (0.64) | — | |
| SCHEMBL4314125 | 0.76 | KDM4E (0.52) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | WYETH (US) | 2009-12-31 | — | — | US | claimed |
| WO-2009143404-A1 | PIPERAZINE METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLUR5) NEGATIVE ALLOSTERIC MODULATORS FOR ANXIETY/DEPRESSION | WYETH (US) | 2009-11-26 | — | — | WO | claimed |
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | GRM5, GRIK5, GRM1 | KDM4E 1411/4885ALDH1A1 3104/4885TDP1 3895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.